The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.
Source link
The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.
Source link
